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ENDOCRINOLOGY

Amiodarone-Induced Thyrotoxicosis and
Ventricular Arrhythmias: Case Report and Review
of the Literature
Ashish Shah, MD

INTRODUCTION
Amiodarone is a common drug used to treat arrhythmias
and its side effects are diverse. An important adverse effect
is amiodarone-induced thyrotoxicosis (AIT), which can
potentially lead to a pro-arrythmogenic state. There have
been limited studies on the pathogenesis of how thyrotoxicosis increases the risk of ventricular arrhythmias, which
causes providers to face a therapeutic challenge in patients
who require this medication for the prevention of life
threatening arrhythmias. This case report will present a
patient with a left ventricular assist device (LVAD) who had
recurrent ventricular arrhythmias on chronic amiodarone
therapy in the setting of AIT.

CASE PRESENTATION
A 50 year old male with history of non-ischemic cardiomyopathy (EF 15%) and an LVAD awaiting transplant presented
to the hospital in ventricular fibrillation/torsades de pointes
requiring electrical cardioversion. His other past medical
history included hypertension, obstructive sleep apnea,
hyperlipidemia, chronic kidney disease and ventricular
tachycardia status post implantable cardioverter defibrillator
(ICD) placement. The patient’s ICD was removed a year
prior to admission due to device endocarditis, MRSA/MSSA
bacteremia, and epidural abscess/spinal osteodiscitis. Due
to the history of ventricular tachyarrhythmias and removal
of the ICD, he was on chronic amiodarone therapy (200mg
per day) for the past 1.5 years.
On admission he denied any symptoms of thyroid
dysfunction such as weight changes, temperature
sensitivity, recent fractures, fatigue/weakness, changes in

bowel movements, hair loss, or changes in sleep. On
physical exam, his vital signs were stable following
cardioversion and he appeared clinically euthyroid without
signs of thyroid associated ophthalmopathy (TAO), moist
palms or dry skin, tremor, peripheral edema, or abnormal
skin temperature. His thyroid exam was normal. Significant
laboratory studies are shown in Table 1.

DIFFERENTIAL DIAGNOSIS
Based on the laboratory values, the differential includes
thyroid diseases such as Graves’ Disease, thyroiditis, toxic
nodule or toxic multinodular goiter or AIT type 1 or type
2. The combination of radioactive iodine uptake (RAIU)
and scan, the detection of autoantibodies, and color flow
Doppler sonography can help narrow down this
differential.

OUTCOME AND FOLLOW-UP
During the patient’s hospital stay, he was continued on an
increased dose of amiodarone therapy and a new ICD
was placed successfully without complications. A thyroid
ultrasound revealed a hypoechoic right thyroid nodule
measuring 1.6 x 0.9 x 1.1 cm and normal thyroid size. A
radioactive thyroid uptake and scan showed markedly
reduced thyroid activity. An ultrasound guided biopsy of
the thyroid nodule showed minimal blood flow through
the nodule using Doppler evaluation. The FNA was
performed to rule out malignancy in the setting of being
on the transplant list and the pathology was a benign
follicular nodule. Thyroid Stimulating Immunoglobulins
were not elevated. He was diagnosed as having type 2
AIT. Upon discharge, the patient’s amiodarone dose was

Table 1: Thyroid Function Studies
1 month
after hospital
admission

During
hospital
admission

2 months
prior to
admission

1 year prior to
admission (6 months on
amiodarone therapy)

2 years prior to
admission (before
amiodarone therapy)

0.58

<0.02

<0.02

5.21

2.40

Free T4 (ng/dL)
(normal 0.7-1.7)

1.3

1.9

3.6

1.5

Not checked

Free T3 (ng/dL)
(normal 2-4.2)

1.9

3.8

Not
checked

Not checked

Not checked

Thyroid Stimulating
Hormone (uIU/mL)
(normal 0.3-5)
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Table 2: Amiodarone-induced thyrotoxicosis classification1
Type 1

Type 2

Present

Absent

RAIU

Low/normal/increased

Low

Interleukin 6 serum level

Normal/slight increase

Elevated

Increased color flow

Decreased color flow

Response to thionamides

Yes

No

Response to perchlorate

Yes

No

Response to glucocorticoids

No

Yes

Subsequent hypothyroidism

No

Possible

Goiter/thyroid autoantibodies

Color flow Doppler ultrasound

increased to 400mg daily. The patient was followed as an
outpatient and his thyroid function tests normalized
within one month of hospitalization without requiring
therapy. His thyroid function tests continue to be closely
monitored and he is currently listed for heart transplant.

Thyrotoxicosis can occur at any point during amiodarone
therapy, with an average length of treatment being three
years before occurrence1. AIT has been classified into two
types (type 1 AIT and type 2 AIT), although distinguishing
between both types can be difficult.

DISCUSSION

In type 1 AIT, excessive thyroid hormone synthesis is
induced by the iodine load associated with amiodarone
therapy1. These patients typically have a prior thyroid
abnormality such as diffuse or nodular goiter or latent
Graves’ disease and live in a geographic area that is slightly
iodine-deficient1. Their thyroid gland does not respond to
the iodine load which would normally decrease the
synthesis of thyroid hormone, but it rather continues to
uptake more iodine and synthesize more thyroid hormone
1
. This type of AIT has increased RAIU and normal or
slightly elevated serum interleukin 6 levels, a cytokine that
indicates thyroid cell destruction, and thus there is no
significant thyroid cell destruction in type 1 AIT1. On
ultrasound with color flow Doppler, there is an increase in
color flow indicating hypervascularity as well as increased
functioning of the thyroid1.

Amiodarone is an iodine rich drug that is used commonly
in the treatment of both ventricular and atrial arrhythmias.
Amiodarone affects multiple organ systems and can have
varying effects on the thyroid as well. It can result in
abnormalities in thyroid function tests as well as clinically
apparent thyrotoxicosis or even hypothyroidism.
Amiodarone is 37% iodine by weight and is structurally
similar to T41. Taking 200mg of amiodarone daily releases
approximately 7mg of iodide per day, which far exceeds
the daily recommended optimal dose of iodine of 150ug1.
Amiodarone and its metabolite, desethylamiodarone,
have long half-lives of approximately 53 days and 61 days
respectively1. As a result of the increased iodine content,
a very long half life, and systemic distribution into the
adipose tissues, amiodarone can continue to cause
clinical effects after cessation of therapy.
For patients who are on chronic amiodarone therapy and
are clinically euthyroid, thyroid function tests typically
display an increased serum T4 concentration and a
decreased serum T3 concentration1. Amiodarone inhibits
the type 1-5’-deiodinase in peripheral tissues, which is
responsible for the conversion of T4 to T31. Typically,
patients will have serum T4 concentrations at the upper
limit of normal and serum T3 concentrations within the
low normal range. The TSH in these patients are usually
normal however initially after starting amiodarone therapy
the TSH can be elevated as was seen in our patient after
he was on therapy for 6 months1.
AIT has an incidence of 14-18% of patients on chronic
amiodarone therapy1. A significant risk factor for this
adverse effect is taking a dose of 200mg daily 1.
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Patients with type 2 AIT typically have a normal thyroid
gland prior to amiodarone therapy and do not have
thyroid autoantibodies1. They have very low RAIU and
elevated serum interleukin 6 levels1. On ultrasound with
color flow Doppler, there is typically less color flow in any
area of the thyroid indicating decreased vascularity and
decreased function of the thyroid gland1. These features
of type 2 AIT infer that the pathophysiology involves
thyroid cell destruction with evidence follicular damage1.
The damaged follicles then release their preformed
thyroid hormones leading to clinical symptoms of AIT.
Table 2 summarizes the classification of AIT.
Treatment of type I AIT is primarily blocking organification
of excess iodine and the synthesis of thyroid hormones1.
Higher doses of thionamides such as methimazole or
propylthiouracil are utilized. Another drug used to block
the excess iodine from entering the thyroid is potassium
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perchlorate (although not available in the US), which can
be combined with the thionamides. Treatment of type 2
AIT is primarily with high dose steroids (40-60mg/day)
due to their anti-inflammatory and membrane stabilizing
effects on the thyroid along with inhibition of
5’-deiodinase1. If a patient has features of both type 1 and
type 2 AIT, a combination of thionamides/potassium
perchlorate and steroids can be used. If these treatment
options are not successful, the last options are radioactive
iodine (for type 1) or total thyroidectomy (for both).
In our patient, his T4 was elevated in the setting of a
suppressed TSH both two months prior to admission and
on admission. He had a right thyroid nodule but no
known autoantibodies or prior thyroid dysfunction. His
RAIU was suppressed throughout the thyroid gland.
Interleukin 6 levels were not obtained. On thyroid
ultrasound, there was no increased color flow uptake. As
a result, the patient was diagnosed with a likely mild case
of type 2 AIT. Clinically, he had limited symptoms of
thyrotoxicosis which may have been secondary to his
previously prescribed beta-blocker (carvedilol).
The more interesting finding is that this patient had an
episode of ventricular fibrillation/torsades de pointes in
the setting of type 2 AIT. A recent study done in Japan on
patients on chronic amiodarone therapy showed that
recurrent sustained ventricular tachycardia was significantly
higher with thyrotoxicosis than in the euthyroid state4.
Holter monitoring of these patients with thyrotoxicosis
actually showed that the heart rate along with the number
of ventricular premature complexes significantly
increased4. One case report in Australia documented a
patient on chronic amiodarone therapy for ventricular
ectopy developing a coronary vasospasm and recurrent
ventricular fibrillation in the setting of type 2 AIT5. It is
difficult to conclude whether our patient’s type 2 AIT had
any role in contributing to his ventricular fibrillation/
torsades de pointes episode prior to admission or whether
this was the progression of his non-ischemic cardiomyopathy. It seems fair to conclude that triggers for his
arrhythmia are multifactorial in nature. One recent study
showed that the rate of major adverse cardiovascular
events (cardiovascular mortality, myocardial infarction,
stroke and heart failure, or ventricular arrhythmias requiring
hospitalization) is 2.7 fold greater for those patients on
long term amiodarone therapy who develop AIT than
those who do not develop AIT, with ventricular arrhythmias
being the most frequent type of event6. It has also been
found that in the setting of AIT, severe left ventricular
dysfunction is associated with increased mortality7.
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In conclusion, this case displays the effects of chronic
amiodarone therapy on thyroid function. Clinicians must
weigh the risks and benefits of using this anti-arrhythmic in
the setting of a patient’s underlying cardiomyopathy. Given
this patient’s history of ventricular arrhythmias, the benefit
of being on amiodarone therapy greatly outweighs the risks
of developing thyrotoxicosis. However after presenting to
the hospital with episodes of ventricular fibrillation/torsades
de pointes in the setting of type 2 AIT, one has to carefully
follow the thyroid function tests to ensure biochemical
normalization in order to minimize the risk for increased
ventricular arrhythmia burden in addition to his worsening
left ventricular ejection fraction. Overall, this is a unique
case of an LVAD patient being bridged to transplant with
recurrent ventricular arrhythmia on chronic amiodarone
therapy who developed type 2 AIT. The management of
these arrhythmias in the setting of AIT need to be further
studied in order to balance the beneficial anti-arrhythmic
properties of amiodarone with its harmful ability to cause
thyrotoxicosis leading to a pro-arrythmogenic state.
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